Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rFVIIa; NovoSeven®), which provides improved convenien...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Francesco Demartis, Angelika Batorova, Hervé Chambost, Peyman Eshghi, Mehran Karimi, Kaan Kavakli, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer Vestergaard, Gary Benson
Format: Artigo
Langue:Inglês
Publié: Georg Thieme Verlag KG 2017-07-01
Collection:TH Open
Sujets:
bleeding
efficacy
eptacog alfa activated
novoseven®
rfviia
Accès en ligne:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1608943
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Chargement en cours...

Documents similaires